Phase 2aData readout

Nimacimab

Obesity

SKYESkye Bioscience

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: Nimacimab
Development stage: Phase 2a
Event type: Data readout
Indication: Obesity

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 2a data readout for Nimacimab in Obesity. The expected timing is based on the latest available company guidance and may change.

Development notes

CBeyond trial. 9/2/25- Enrollment completed. 10/6/25- Topline data reported, did not meet primary endpoint. 11/7/25– Data presented at ObesityWeek'25. 01/12/26:- CBeyond Ph2a DMC confirmed favorable safety. Extension data Q1 2026; 52-week topline and Ph2b trial initiation Q3 2026. 01/12/26:- CBeyond 2 adaptive Ph2b obesity trial to be finalized with regulators Q1 2026 and initiated Q3 2026. 01/21/26:- Keystone poster on nimacimab obesity DIO mouse model and GLP-1 combo data on 1/28/2026. 02/02/26:- Interim 52-week CBeyond extension combo data positive; full Phase 2a topline expected Q3 2026. 03/10/26:- CBeyond Part C higher-dose Ph2a initiated; topline Q4 2026. New 26/52-week combo and weight-regain data. 04/02/26:- First patient dosed in CBeyond Part C expansion; topline data expected Q4 2026; FDA provided written feedback. 04/07/26:- Present at GLP-1-Based Therapeutics Summit on Apr 16, 2026; discussed CBeyond Ph2a nimacimab with Wegovy. 05/11/26:- CBeyond Part C Cohort1 enrolling; CRC review May 18 2026; Q2 Cohort2 start,enrollment+formulation work; Q4 2026 topline,Ph2b design. 05/20/26:- CRC approved opening CBeyond Part C Cohort 2 after favorable 4-week safety review.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

What is being tracked?

This catalyst tracks a Phase 2a data readout for Nimacimab in Obesity. The expected timing is based on the latest available company guidance and may change.